| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 12 Feb 2026 | 4 Feb 2026 |
| Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2026 ,inter alia, to consider and approve unaudited Financial Results (Standalone And Consolidated) Of The Company For The Third Quarter And Nine Months Ended 31st December, 2025 And Other Business if any. Outcome of the meeting held today. (As per BSE announcement dated on : 12.02.2026) | ||
| Board Meeting | 13 Nov 2025 | 5 Nov 2025 |
| Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve Standalone and Consolidated Unaudited Financial Results of the Company for the Quarter and Half Year ended 30.09.2025. UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30.09.2025 (As per BSE Announcement dated on: 13.11.2025) | ||
| Board Meeting | 7 Aug 2025 | 28 Jul 2025 |
| Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2025 inter alia to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30 2025. UN-AUDITED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED ON 30-JUNE-2025 (As per BSE Announcement Dated on 07/08/2025) | ||
| Board Meeting | 22 May 2025 | 15 May 2025 |
| Lincoln Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2025 inter alia to consider and approve Audited (standalone and consolidated) financial results of the Company for the quarter and year ended on March 31 2025. Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity shares of face value 10/- each for the Financial year Ended 31st March, 2025 subject to approval of the members at the ensuing A.G.M of the Company. (As Per BSE Announcement dated on 22.05.2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
